Physician profile
Martha E Stewart
NPI 1972535284
$4,484.70
in general payments reported to CMS, 2019-2025
34 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,011 · 2020: $583 · 2021: $383 · 2022: $481 · 2023: $349 · 2024: $444 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $597.55 | 2019-2025 | |
| Almirall LLC | $368.31 | 2019-2025 | Klisyri, Seysara |
| Allergan, INC. | $330.09 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $268.52 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Incyte Corporation | $266.34 | 2021-2025 | Opzelura |
| Medimetriks Pharmaceuticals, INC. | $243.09 | 2019-2025 | Neo-Synalar |
| Galderma Laboratories, L.P. | $228.13 | 2019-2024 | Aklief, Oracea, Epsolay |
| Amgen INC. | $227.45 | 2020-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $220.09 | 2019-2024 | |
| Ucb, INC. | $218.26 | 2019-2022 | |
| Dermira, INC. | $164.34 | 2019-2020 | |
| Abbvie INC. | $129.96 | 2019-2024 | Rinvoq |
| Genzyme Corporation | $106.39 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $102.03 | 2020-2021 | |
| Leo Pharma INC. | $100.85 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $100.00 | 2024 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Sun Pharmaceutical Industries INC. | $97.73 | 2020-2022 | |
| Janssen Biotech, INC. | $88.74 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $73.20 | 2022-2023 | Apexicon E |
| Dermavant Sciences, INC. | $70.14 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $61.53 | 2019-2020 | |
| Lilly USA, LLC | $59.78 | 2019-2020 | |
| Merz North America, INC. | $54.32 | 2019 | |
| Arcutis Biotherapeutics, INC. | $50.42 | 2023-2024 | Zoryve |
| Mission Pharmacal Company | $43.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.34 | 2019 | |
| Epi Health, LLC | $26.42 | 2019 | |
| Celgene Corporation | $20.85 | 2019 | |
| Organon LLC | $17.78 | 2025 | Vtama |
| Aclaris Therapeutics, INC. | $16.38 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.